PRECISION-tMN
| Patologia: | Neoplasie mieloidi |
| Area Tematica: | Medicina Personalizzata |
| Data di Inizio Progetto: | 01/01/2026 |
| Data di Fine Progetto: | 01/01/2029 |
| Finanziamento: | € 500.000,00 |
| Partenariato | IRCCS Humanitas (Milano) Josep Carreras Leukaemia Research Institute (Spagna) Istituto europeo di oncologia (Milano) University Leipzig (Germania) Gebze Technical University (Turchia) Fundación Josep Carreras contra la Leucemi (Spagna) |
PRECISION-tMN aims to revolutionize the clinical management of therapy-related myeloid neoplasms (t-MN) by integrating precision medicine approaches with cutting-edge molecular and computational analyses. t-MN is a severe complication of prior cancer treatments, characterized by poor
prognosis and resistance to standard therapies. Despite advancements in molecular profiling, the
mechanisms driving disease progression and therapeutic resistance remain poorly understood, limiting the development of effective treatment strategies.
This consortium leverages a multidisciplinary and transnational collaboration to dissect the interplay between genetic mutations, epigenetic modifications, transcriptional alterations, and immune
dysregulation in t-MN. By combining multi-omics approaches (genomics, epigenomics and transcriptomics) with advanced bioinformatics, artificial intelligence and clinical data, the project aims
to identify pharmacogenomic biomarkers for risk stratification, and therapeutic targeting. State-of-the-art patient-derived models and single-cell technologies will be employed to explore disease heterogeneity and response to treatment. PRECISION-tMN brings together leading academic institutions, hospitals, and patient associations, ensuring access to large patient cohorts, high-quality biobanks, standardized diagnostic platforms and previous cohorts of patients and data. This collaborative effort will validate novel therapeutic targets and accelerate their clinical translation, ultimately paving the way for personalized treatment strategies. The project will also contribute to data harmonization, knowledge dissemination, and training initiatives, fostering sustainable progress in precision oncology for t -MN.